United Kingdom - English - myHealthbox

dr. reddy’s laboratories (uk) ltd. - bosentan - film-coated tablet - 125mg - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii. efficacy has been shown in: • primary (idiopathic and heritable) pulmonary arterial hypertension • pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease • pulmonary arterial hypertension associated with congenital systemic-topulmonary shunts and eisenmenger’s physiology

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddy's laboratories australia pty ltd - irbesartan -

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - omeprazole 10mg;   - modified release capsule - 10 mg - active: omeprazole 10mg   excipient: capsugel purple op.c046 capsugel yellow op.c305 crospovidone hypromellose isopropyl alcohol magnesium stearate mannitol meglumine methacrylic acid - ethyl acrylate copolymer opacode black s-1-27794 poloxamer povidone purified water triethyl citrate

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - sertraline hydrochloride 111.92mg equivalent to sertraline 100 mg - film coated tablet - 100 mg - active: sertraline hydrochloride 111.92mg equivalent to sertraline 100 mg excipient: calcium hydrogen phosphate colloidal silicon dioxide hyprolose magnesium stearate microcrystalline cellulose opadry white oy-58900 polysorbate 80 sodium starch glycolate - sertraline is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - sertraline hydrochloride 55.96mg equivalent to sertraline 50 mg - film coated tablet - 50 mg - active: sertraline hydrochloride 55.96mg equivalent to sertraline 50 mg excipient: calcium hydrogen phosphate colloidal silicon dioxide hyprolose magnesium stearate microcrystalline cellulose opadry white oy-58900 polysorbate 80 sodium starch glycolate - sertraline is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

Malta - English - Medicines Authority

dr. franz kohler chemie gmbh werner-von-siemens-str. 22-28, d-64625, bensheim, germany - lormetazepam - solution for infusion or injection - lormetazepam 2 mg - psycholeptics

European Union - English - EMA (European Medicines Agency)

dr. friedrich eberth arzneimittel gmbh - lasofoxifene tartrate - osteoporosis, postmenopausal - sex hormones and modulators of the genital system, - fablyn is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated (see section 5.1).when determining the choice of fablyn or other therapies, including oestrogens, for a postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - bosentan monohydrate, quantity: 129.082 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; sodium starch glycollate type a; povidone; glycerol dibehenate; magnesium stearate; hypromellose; titanium dioxide; triacetin; purified talc; iron oxide yellow; iron oxide red; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; sodium starch glycollate type a; povidone; glycerol dibehenate; magnesium stearate; hypromellose; titanium dioxide; triacetin; purified talc; iron oxide yellow; iron oxide red; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - palonosetron hydrochloride, quantity: 280 microgram (equivalent: palonosetron, qty 250 microgram) - injection, solution - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - palonosetron injection is indicated for prevention of nausea and vomiting induced by cytotoxic chemotherapy.